{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:09:09Z","timestamp":1787620149111,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"The Danish Regions","award":["14\/217"],"award-info":[{"award-number":["14\/217"]}]},{"name":"Lilly and Herbert Hansen Foundation"},{"DOI":"10.13039\/100009678","name":"Scandinavian Society of Antimicrobial Chemotherapy","doi-asserted-by":"publisher","award":["SLS-403571\/503521"],"award-info":[{"award-number":["SLS-403571\/503521"]}],"id":[{"id":"10.13039\/100009678","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Society in Copenhagen"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EClinicalMedicine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.eclinm.2019.06.009","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T22:51:20Z","timestamp":1563576680000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0670-9996","authenticated-orcid":false,"given":"Filip","family":"Jans\u00e5ker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Th\u00f8nnings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik Bo\u00ebtius","family":"Hertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kallemose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"V\u00e6rnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Benfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Frimodt-M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny Dahl","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2019.06.009_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ucl.2007.09.004","article-title":"Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis","volume":"35","author":"Nicolle","year":"2008","journal-title":"Urol Clin North Am"},{"issue":"6","key":"10.1016\/j.eclinm.2019.06.009_bb0010","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3122\/15572625-13-6-392","article-title":"Quality of life in women with urinary tract infections: is benign disease a misnomer?","volume":"13","author":"Ellis","year":"2000","journal-title":"J Am Board Fam Pract"},{"key":"10.1016\/j.eclinm.2019.06.009_bb0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1477-7525-3-45","article-title":"Women's quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment","volume":"3","author":"Ernst","year":"2005","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"10.1016\/j.eclinm.2019.06.009_bb0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ccc.2013.03.014","article-title":"Urinary tract infection","volume":"29","author":"Nicolle","year":"2013","journal-title":"Crit Care Clin"},{"issue":"5","key":"10.1016\/j.eclinm.2019.06.009_bb0025","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.eclinm.2019.06.009_bb0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/jac\/46.suppl_1.35","article-title":"Pivmecillinam in the treatment of urinary tract infections","volume":"46","author":"Nicolle","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2019.06.009_bb0035","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijid.2017.03.012","article-title":"Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis","volume":"58","author":"Pinart","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2019.06.009_bb0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/02813430802535312","article-title":"Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial","volume":"27","author":"Bjerrum","year":"2009","journal-title":"Scand J Prim Health Care"},{"issue":"1","key":"10.1016\/j.eclinm.2019.06.009_bb0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/02813430601183074","article-title":"Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project","volume":"25","author":"Ferry","year":"2007","journal-title":"Scand J Prim Health Care"},{"issue":"4","key":"10.1016\/j.eclinm.2019.06.009_bb0050","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apm.12147","article-title":"Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women","volume":"122","author":"Monsen","year":"2014","journal-title":"Acta Pathol Microbiol Immunol Scand"},{"issue":"7","key":"10.1016\/j.eclinm.2019.06.009_bb0055","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/00365540110080728","article-title":"Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women","volume":"34","author":"Nicolle","year":"2002","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2019.06.009_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijantimicag.2011.09.013","article-title":"Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited","volume":"39","author":"Kahlmeter","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 2","key":"10.1016\/j.eclinm.2019.06.009_bb0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0924-8579(03)00235-8","article-title":"Pivmecillinam--therapy of choice for lower urinary tract infection","volume":"22","author":"Graninger","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eclinm.2019.06.009_bb0070","series-title":"Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark","author":"DANMAP","year":"2017"},{"issue":"9","key":"10.1016\/j.eclinm.2019.06.009_bb0075","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/jac\/dky230","article-title":"Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study","volume":"73","author":"Bollestad","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.eclinm.2019.06.009_bb0080","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/dkt404","article-title":"Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections","volume":"69","author":"Jansaker","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.eclinm.2019.06.009_bb0085","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1186\/s12879-016-2022-0","article-title":"The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections - a randomized, double-blinded, placebo-controlled clinical trial study protocol","volume":"16","author":"Jansaker","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"20","key":"10.1016\/j.eclinm.2019.06.009_bb0090","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1001\/jama.287.20.2701","article-title":"DOes this woman have an acute uncomplicated urinary tract infection?","volume":"287","author":"Bent","year":"2002","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eclinm.2019.06.009_bb0095","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1464-410X.2005.05630.x","article-title":"Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI symptom assessment questionnaire","volume":"96","author":"Clayson","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eclinm.2019.06.009_bb0100","series-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2015"},{"key":"10.1016\/j.eclinm.2019.06.009_bb0105","series-title":"The European committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of MICs and zone diameters - version 3.1","year":"2013"},{"issue":"4","key":"10.1016\/j.eclinm.2019.06.009_bb0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1198-743x.2001.00237.x","article-title":"European guidelines for urinalysis: a collaborative document produced by European clinical microbiologists and clinical chemists under ECLM in collaboration with ESCMID","volume":"7","author":"Aspevall","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"20","key":"10.1016\/j.eclinm.2019.06.009_bb0115","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1302186","article-title":"Voided midstream urine culture and acute cystitis in premenopausal women","volume":"369","author":"Hooton","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2019.06.009_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002569","article-title":"Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-a double-blind, randomized non-inferiority trial","volume":"15","author":"Vik","year":"2018","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.eclinm.2019.06.009_bb0125","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jac\/dki451","article-title":"Activity of mecillinam against ESBL producers in vitro","volume":"57","author":"Thomas","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.eclinm.2019.06.009_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085889","article-title":"High rate of per Oral Mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli","volume":"9","author":"Soraas","year":"2014","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.eclinm.2019.06.009_bb0135","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose Fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.eclinm.2019.06.009_bb0140","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamainternmed.2016.3646","article-title":"The new antibiotic mantra-\"shorter is better\"","volume":"176","author":"Spellberg","year":"2016","journal-title":"JAMA Intern Med"}],"container-title":["EClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537019301026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537019301026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:59:57Z","timestamp":1762887597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537019301026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":28,"alternative-id":["S2589537019301026"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2019.06.009","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial","name":"articletitle","label":"Article Title"},{"value":"EClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2019.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}